UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003651
Receipt number R000004420
Scientific Title A Randomized Phase III Trial of Adjuvant Chemotherapy with UFT following Curative Radiation Therapy for Locally Advanced Cervical Cancer
Date of disclosure of the study information 2010/05/24
Last modified on 2023/05/31 15:00:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized Phase III Trial of Adjuvant Chemotherapy with UFT following Curative Radiation Therapy for Locally Advanced Cervical Cancer

Acronym

A Randomized Trial of Adjuvant Chemotherapy with UFT following Curative Therapy for Locally Advanced Cervical Cancer

Scientific Title

A Randomized Phase III Trial of Adjuvant Chemotherapy with UFT following Curative Radiation Therapy for Locally Advanced Cervical Cancer

Scientific Title:Acronym

A Randomized Trial of Adjuvant Chemotherapy with UFT following Curative Therapy for Locally Advanced Cervical Cancer

Region

Japan


Condition

Condition

Stage Ib2-IVa cervical cancer with Curative Radiation Therapy

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Usefulness of Adjuvant Chemotherapy with UFT following Curative Therapy for patients with StageIb2-IVa cervical cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase III


Assessment

Primary outcomes

Progression-free survival

Key secondary outcomes

Overall Suvival/Adverse event/Quality of Life/Cost effectiveness


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Observation

Interventions/Control_2

UFT 300 or 400mg/Day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Female

Key inclusion criteria

1)Pathologicaly confirmed cervical cancer(squamous cell carcinoma,adenosquamous carcinoma,adenocarcinoma)
2)FIGO: Ib2, IIa, IIb, IIIa, IIIb, IVa
3)Patients who have received CCRT within 3-12 weeks and determined to be PR or CR by CT or MRI.
4)Age: 20 years old-75 years old
5)Performance status: ECOG 0-2
6)Adequate organ functions.
7)Patients who have signed to an approved informed consent.

Key exclusion criteria

1)Patients who have received hysterectomy after radiation therapy.
2)Patients with uterine stump cancer.
3)Patients who have received NAC.
4)Patients with active infection.
5)Patients who have myocardial infarction or unstable angina or uncontrolled arrhythmia within 6 months.
6)Patients with severe complications (uncontrolled hypertension,uncontrolled diabetes,bleeding tendency,or rheumatology).
7)Patients who have had any other cancer within the past 5 years.
8)Patients with watery diarrhea.
9)Patients with psychiatric disease.
10)Patients who are pregnant or breast feeding.
11)Patients who have a history of hypersensitivity to UFT
12)Patients who are considered to be inappropriate for this study judged by the treating physician

Target sample size

350


Research contact person

Name of lead principal investigator

1st name Keiichi
Middle name
Last name Fujiwara

Organization

Saitama Medical University International Medical Center

Division name

Gynecologic Oncology

Zip code

350-1298

Address

1397-1 Yamane,Hidaka-City Saitama

TEL

042-984-4111

Email

fujawara@saitama-med.ac.jp


Public contact

Name of contact person

1st name Keiichi
Middle name
Last name Fujiwara

Organization

GOTIC002 Coordinating Office

Division name

Saitama Medical University International Medical Center

Zip code

350-1298

Address

1397-1 Yamane,Hidaka-City Saitama

TEL

042-984-4111

Homepage URL


Email

fujawara@saitama-med.ac.jp


Sponsor or person

Institute

Gynecologic Oncology Trial and Investigation Consortium

Institute

Department

Personal name



Funding Source

Organization

Gynecologic Oncology Trial and Investigation Consortium

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Saitama Medical University Certified Review Board

Address

1397-1, Yamane, Hidaka-City, Saitama-Pref, Japan

Tel

042-984-4122

Email

tokutei@saitama-med.ac.jp


Secondary IDs

Secondary IDs

YES

Study ID_1

jRCTs031180244

Org. issuing International ID_1

Japan Registry of Clinical Trials(jRCT)

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

埼玉医科大学国際医療センター(埼玉県)、
鳥取大学医学部附属病院(鳥取県)、
久留米大学病院(福岡県)、
埼玉医科大学総合医療センター(埼玉県)、
埼玉県立がんセンター(埼玉県)、
筑波大学附属病院(茨城県)、
獨協医科大学病院(栃木県)、
自治医科大学附属病院(栃木県)、
群馬大学医学部附属病院(群馬県)、
立正佼成会附属佼成病院(東京都)、
群馬県立がんセンター(群馬県)、
鳥取市立病院(鳥取県)、
九州大学病院(福岡県)、
四国がんセンター(愛媛県)、
順天堂大学医学部附属順天堂医院(東京都)、
徳島大学病院(徳島県)、
広島市立広島市民病院(広島県)、
県立広島病院(広島県)、
東京慈恵会医科大学附属病院(東京都)、
高崎総合医療センター(群馬県)、
聖マリアンナ医科大学病院(神奈川県)、
東京医科歯科大学医学部附属病院(東京都)、
千葉大学医学部附属病院(千葉県)、
大阪大学医学部附属病院(大阪府)、
愛媛大学医学部附属病院(愛媛県)、
東京慈恵会医科大学附属第三病院(東京都)、
杏林大学医学部附属病院(東京都)、
鹿児島大学病院(鹿児島県)、
北海道大学病院(北海道)、
琉球大学病院(沖縄県)、
東京慈恵会医科大学附属柏病院(千葉県)、
兵庫県立がんセンター(兵庫県)、
香川県立中央病院(香川県)、
鹿児島医療センター(鹿児島県)、
聖マリア病院(福岡県)、
茨城県立中央病院(茨城県)、
熊本大学医学部附属病院(熊本県)、
北里大学病院(神奈川県)、
聖隷浜松病院(静岡県)、
旭川医科大学病院(北海道)、
三重大学医学部附属病院(三重県)、
岩手医科大学附属病院(岩手県)、
東京医科大学病院(東京都)


Other administrative information

Date of disclosure of the study information

2010 Year 05 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2010 Year 04 Month 26 Day

Date of IRB

2010 Year 05 Month 12 Day

Anticipated trial start date

2010 Year 05 Month 21 Day

Last follow-up date

2021 Year 10 Month 31 Day

Date of closure to data entry

2022 Year 02 Month 28 Day

Date trial data considered complete

2022 Year 03 Month 14 Day

Date analysis concluded

2022 Year 08 Month 09 Day


Other

Other related information



Management information

Registered date

2010 Year 05 Month 21 Day

Last modified on

2023 Year 05 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004420


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name